Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter N Morcos

Showing results (31-40 of 58) with videos related to

Pageof 6
Sort By:
Clinical Pharmacology in Drug Development|August 23, 2016
Effect of Food and Esomeprazole on the Pharmacokinetics of Alectinib, a Highly Selective ALK Inhibitor, in Healthy SubjectsPeter N Morcos, Elena Guerini, Neil Parrott, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 30, 2023
Copanlisib population pharmacokinetics from phase I-III studies and exposure-response relationships in combination with rituximabPeter N Morcos, Jonathan Moss, Rupert Austin, et al.
Heliyon|July 21, 2017
Metabolites of alectinib in human: their identification and pharmacological activityMika Sato-Nakai, Kosuke Kawashima, Toshito Nakagawa, et al.
Clinical Pharmacology and Therapeutics|May 27, 2021
Quantitative Clinical Pharmacology Supports the Bridging From i.v. Dosing and Approval of s.c. Rituximab in B-Cell Hematological MalignanciesCandice Jamois, Ekaterina Gibiansky, Leonid Gibiansky, et al.
Biopharmaceutics & Drug Disposition|June 11, 2011
Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasibleMicaela B Reddy, Alyson Connor, Barbara J Brennan, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 21, 2024
Population pharmacokinetics of imetelstat, a first-in-class oligonucleotide telomerase inhibitorMario González-Sales, Ashley L Lennox, Fei Huang, et al.
Antimicrobial Agents and Chemotherapy|June 27, 2012
Safety, tolerability, and pharmacokinetics of intravenous oseltamivir: single- and multiple-dose phase I studies with healthy volunteersBarbara J Brennan, Brian Davies, Georgina Cirrincione-Dall, et al.
Clinical and Translational Science|November 18, 2024
Imetelstat, a novel, first-in-class telomerase inhibitor: Mechanism of action, clinical, and translational scienceAshley L Lennox, Fei Huang, Melissa Kelly Behrs, et al.
Clinical and Translational Science|April 12, 2023
Model-informed approach to support pediatric dosing for the pan-PI3K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumorsPeter N Morcos, Jan Schlender, Rolf Burghaus, et al.
Clinical Pharmacology in Drug Development|August 23, 2016
Clinical Drug-Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor AlectinibPeter N Morcos, Yumi Cleary, Elena Guerini, et al.
Pageof 6

Showing results (31-40 of 58) with videos related to

Sort By:
Pageof 6
Clinical Pharmacology in Drug Development|August 23, 2016
Effect of Food and Esomeprazole on the Pharmacokinetics of Alectinib, a Highly Selective ALK Inhibitor, in Healthy SubjectsPeter N Morcos, Elena Guerini, Neil Parrott, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 30, 2023
Copanlisib population pharmacokinetics from phase I-III studies and exposure-response relationships in combination with rituximabPeter N Morcos, Jonathan Moss, Rupert Austin, et al.
Heliyon|July 21, 2017
Metabolites of alectinib in human: their identification and pharmacological activityMika Sato-Nakai, Kosuke Kawashima, Toshito Nakagawa, et al.
Clinical Pharmacology and Therapeutics|May 27, 2021
Quantitative Clinical Pharmacology Supports the Bridging From i.v. Dosing and Approval of s.c. Rituximab in B-Cell Hematological MalignanciesCandice Jamois, Ekaterina Gibiansky, Leonid Gibiansky, et al.
Biopharmaceutics & Drug Disposition|June 11, 2011
Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasibleMicaela B Reddy, Alyson Connor, Barbara J Brennan, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 21, 2024
Population pharmacokinetics of imetelstat, a first-in-class oligonucleotide telomerase inhibitorMario González-Sales, Ashley L Lennox, Fei Huang, et al.
Antimicrobial Agents and Chemotherapy|June 27, 2012
Safety, tolerability, and pharmacokinetics of intravenous oseltamivir: single- and multiple-dose phase I studies with healthy volunteersBarbara J Brennan, Brian Davies, Georgina Cirrincione-Dall, et al.
Clinical and Translational Science|November 18, 2024
Imetelstat, a novel, first-in-class telomerase inhibitor: Mechanism of action, clinical, and translational scienceAshley L Lennox, Fei Huang, Melissa Kelly Behrs, et al.
Clinical and Translational Science|April 12, 2023
Model-informed approach to support pediatric dosing for the pan-PI3K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumorsPeter N Morcos, Jan Schlender, Rolf Burghaus, et al.
Clinical Pharmacology in Drug Development|August 23, 2016
Clinical Drug-Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor AlectinibPeter N Morcos, Yumi Cleary, Elena Guerini, et al.
Pageof 6